Tokushima University / Educator and Researcher Directory --- Nakayama, Tomohiko

Search:

Research

Personal Web Page

https://researchmap.jp/nakayamatomohiko (researchmap)

https://orcid.org/0009-0000-2027-9350 (ORCID)

Field of Study

○	Life sciences [Psychiatry]

Subject of Study

Book / Paper

(See https://researchmap.jp/nakayamatomohiko (researchmap) for Published Book / Papers / Presentations.)

Book:

1.	Tomohiko Nakayama : 心的外傷後ストレス障害(PTSD), MEDICAL VIEW CO., LTD., Dec. 2025.
2.	Tomohiko Nakayama and Shusuke Numata : 薬物療法の効果・副作用を評価する, Jun. 2025.

Academic Paper (Judged Full Paper):

1.	Yukiko Tomioka, Masahito Nakataki, Hidehiro Umehara, Tomohiro Yoshida, Hiroya Matsuda, Yui Matsumoto, Mariko Aoki, Yuri Yoshida, Yuichiroh Kamiyama, Tomohiko Nakayama, Naoki Yamada and Shusuke Numata : DNMT gene expression in peripheral leukocytes in schizophrenia and correlations with one-carbon metabolites: folate, total homocysteine, and vitamin B6., Frontiers in Psychiatry, 16, 2026. (Summary) Previous studies have identified alterations in one-carbon metabolism (OCM), including DNA methylation abnormalities, in individuals with schizophrenia. However, the precise etiology of this disorder remains unclear. In the present study, we examined variations in the expression of DNMT1 and DNMT3a-genes implicated in DNA methylation-using peripheral blood leukocytes from Japanese patients with chronic schizophrenia and healthy controls. Additionally, using our previously acquired data, we explored the association between OCM-related factors and DNMT expression levels.Expression levels of DNMT1 and DNMT3a in 215 patients with chronic schizophrenia and 210 healthy controls were quantified using real-time PCR. The Mann-Whitney U test was used to compare the differences between two independent groups. Furthermore, Spearman's correlation analysis was conducted to investigate the relationships between DNMT genes` expression levels and OCM-related metabolites (blood folate, vitamin B6, and total homocysteine).The expression levels of DNMT1 and DNMT3a in peripheral leukocytes were significantly elevated in patients with chronic schizophrenia compared with controls (p = 1.4 × 10-6 and 2.9 × 10-3, respectively). DNMT1 mRNA expression levels exhibited a weak negative correlation with folate exclusively in the aggregated cohort (N = 425) (ρ = -0.16, adjusted q = 5.0 × 10-3), and DNMT3a mRNA expression levels showed a weak negative correlation with vitamin B6 alone in the combined group (ρ = -0.12, adjusted q = 0.03).These findings suggest a potential correlation between nutritional status and elevated expression of DNMT1 and DNMT3a in schizophrenia. Our findings contribute to the understanding of the epigenetic mechanisms associated with schizophrenia and highlight the need for further investigation of the relationships among gene expression, nutritional status, and psychiatric manifestations. (Link to Publication Site) ● Publication site (DOI): 10.3389/fpsyt.2025.1715372 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 41635517 ● Search Scopus @ Elsevier (PMID): 41635517 ● Search Scopus @ Elsevier (DOI): 10.3389/fpsyt.2025.1715372 (DOI: 10.3389/fpsyt.2025.1715372, PubMed: 41635517)
2.	Tomohiko Nakayama, Hidehiro Umehara, Kazuaki Mawatari, Yukiko Tomioka, Tomohiro Yoshida, Hiroya Matsuda, Yui Matsumoto, Masuda Rumiko, Kamishikiryo Toshiharu, Fuchikami Manabu, Masahito Nakataki, Akira Takahashi, Atsushi Tajima, Okada Go and Shusuke Numata : Alterations of Blood Plasma Metabolites, Including Kynurenine and Tryptophan, in Bipolar Disorder., Neuropsychiatric Disease and Treatment, 21, 1067-1073, 2025. (Link to Publication Site) ● Publication site (DOI): 10.2147/NDT.S508021 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-105006852907 (DOI: 10.2147/NDT.S508021, Elsevier: Scopus)
3.	Toshiyuki Shirai, Satoshi Okazaki, Takaki Tanifuji, Shusuke Numata, Tomohiko Nakayama, Tomohiro Yoshida, Kentaro Mouri, Ikuo Otsuka, Noboru Hiroi and Akitoyo Hishimoto : Meta-analyses of epigenetic age acceleration and GrimAge components of schizophrenia or first-episode psychosis., Schizophrenia, 10, 1, 108, 2024. (Summary) Schizophrenia is a common chronic psychiatric disorder that causes age-related dysfunction. The life expectancy in patients with schizophrenia is 10 years shorter than that in the general population because of the higher risk of other diseases, such as cardiovascular diseases. Aging studies based on DNA methylation status have received considerable attention. Several epigenetic age accelerations and predicted values of aging-related proteins (GrimAge and GrimAge2 components) have been analyzed in multiple diseases. However, no studies have investigated up to GrimAge and GrimAge2 components between patients with schizophrenia and controls. Therefore, we aimed to conduct multiple regression analyses to investigate the association between schizophrenia and epigenetic age accelerations and GrimAge and GrimAge2 components in seven cohorts. Furthermore, we included patients with first-episode psychosis whose illness duration was often shorter than schizophrenia in our analysis. We integrated these results with meta-analyses, noting the acceleration of GrimAge, GrimAge2, and DunedinPACE, and increase in adrenomedullin, beta-2 microglobulin, cystatin C, and plasminogen activation inhibitor-1 levels, in patients with schizophrenia or first-episode psychosis. These results corroborated the finding that patients with schizophrenia had an increased risk of diabetes, cardiovascular disease, and cognitive dysfunction from a biological perspective. Patients with schizophrenia and first-episode psychosis showed differences in the results when compared with controls. Such analyses may lead to the development of novel therapeutic targets to patients with schizophrenia or relevant diseases from the perspective of aging in the future. (Tokushima University Institutional Repository) ● Metadata: 2013067 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41537-024-00531-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39548083 ● Summary page in Scopus @ Elsevier: 2-s2.0-85209219391 (Tokushima University Institutional Repository: 2013067, DOI: 10.1038/s41537-024-00531-8, PubMed: 39548083, Elsevier: Scopus)
4.	Tomohiko Nakayama and Shusuke Numata : 統合失調症の精神症状に関する評価尺度—PANSS，BPRS，SANS，SAPS, Seishin Igaku, 66, 5, 520-525, 2024. (Keyword) 統合失調症 (schizophrenia) / 陽性・陰性症状評価尺度 (Positive and Negative Syndrome Scale : PANSS) / 簡易精神症状評価尺度 (Brief Psychiatric Rating Scale : BPRS) / 陰性症状評価尺度 (Scale for the Assessment of Negative Symptoms : SANS) / 陽性症状評価尺度 (Scale for the Assessment of Positive Symptoms : SAPS) (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520018904593324288 (CiNii: 1520018904593324288)
5.	Tomoki Ozaki, Yuta Yoshino, Ayumi Tachibana, Hideaki Shimizu, Takaaki Mori, Tomohiko Nakayama, Kazuaki Mawatari, Shusuke Numata, Junichi Iga, Akira Takahashi, Tetsuro Ohmori and Shu-ichi Ueno : Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer's disease (from the Nakayama Study)., Scientific Reports, 12, 1, 15205, 2022. (Summary) Alzheimer's disease (AD) is a progressive disease, and the number of AD patients is increasing every year as the population ages. One of the pathophysiological mechanisms of AD is thought to be the effect of metabolomic abnormalities. There have been several studies of metabolomic abnormalities of AD, and new biomarkers are being investigated. Metabolomic studies have been attracting attention, and the aim of this study was to identify metabolomic biomarkers associated with AD and mild cognitive impairment (MCI). Of the 927 participants in the Nakayama Study conducted in Iyo City, Ehime Prefecture, 106 were selected for this study as Control (n = 40), MCI (n = 26), and AD (n = 40) groups, matched by age and sex. Metabolomic comparisons were made across the three groups. Then, correlations between metabolites and clinical symptoms were examined. The blood mRNA levels of the ornithine metabolic enzymes were also measured. Of the plasma metabolites, significant differences were found in ornithine, uracil, and lysine. Ornithine was significantly decreased in the AD group compared to the Control and MCI groups (Control vs. AD: 97.2 vs. 77.4; P = 0.01, MCI vs. AD: 92.5 vs. 77.4; P = 0.02). Uracil and lysine were also significantly decreased in the AD group compared to the Control group (uracil, Control vs. AD: 272 vs. 235; P = 0.04, lysine, Control vs. AD: 208 vs. 176; P = 0.03). In the total sample, the MMSE score was significantly correlated with lysine, ornithine, thymine, and uracil. The Barthel index score was significantly correlated with lysine. The instrumental activities of daily living (IADL) score were significantly correlated with lysine, betaine, creatine, and thymine. In the ornithine metabolism pathway, the spermine synthase mRNA level was significantly decreased in AD. Ornithine was decreased, and mRNA expressions related to its metabolism were changed in the AD group compared to the Control and MCI groups, suggesting an association between abnormal ornithine metabolism and AD. Increased betaine and decreased methionine may also have the potential to serve as markers of higher IADL in elderly persons. Plasma metabolites may be useful for predicting the progression of AD. (Keyword) Activities of Daily Living / Aged / Alzheimer Disease / Betaine / Biomarkers / Cognitive Dysfunction / Humans / Lysine / Ornithine / plasma / RNA, Messenger / Thymine (Tokushima University Institutional Repository) ● Metadata: 2012846 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-022-19670-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36075959 ● Search Scopus @ Elsevier (PMID): 36075959 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-022-19670-y (Tokushima University Institutional Repository: 2012846, DOI: 10.1038/s41598-022-19670-y, PubMed: 36075959)
6.	Yukiko Tomioka, Makoto Kinoshita, Hidehiro Umehara, Tomohiko Nakayama, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : Association between serum folate levels and schizophrenia based on sex., Psychiatry and Clinical Neurosciences, 74, 9, 466-471, 2020. (Summary) Our findings suggest that: (i) a low serum folate level may be associated with schizophrenia regardless of sex; and (ii) folate administration may be beneficial for the treatment of schizophrenia. In schizophrenic patients with low serum folate levels, folate administration might result in improvements in high tHcy and an increase in low vitamin B6 levels. (Tokushima University Institutional Repository) ● Metadata: 2008327 (Link to Publication Site) ● Publication site (DOI): 10.1111/pcn.13074 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32445495 ● Search Scopus @ Elsevier (PMID): 32445495 ● Search Scopus @ Elsevier (DOI): 10.1111/pcn.13074 (Tokushima University Institutional Repository: 2008327, DOI: 10.1111/pcn.13074, PubMed: 32445495)

Review, Commentary:

1.	Tomohiko Nakayama and Shusuke Numata : 抗うつ薬の増強療法について，何からどのような用量で開始することがエビデンスのある選択といえるのでしょうか?, Japanese Journal of Psychiatric Treatment, 40, 54-55, 2025.
2.	Tomohiko Nakayama, Yukiko Tomioka, Naoki Yamada, Hidehiro Umehara, Makoto Kinoshita, Masahito Nakataki and Shusuke Numata : 臨床現場におけるたとえ話, Japanese Journal of Psychiatric Treatment, 37, 7, 745-749, Jul. 2022. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520856045142110592 (CiNii: 1520856045142110592)
3.	Tomohiko Nakayama, Shusuke Numata and Tetsuro Ohmori : 精神病性うつ病, Psychiatry, 37, 3, 268-272, Sep. 2020. (Keyword) psychotic depression / catatonic depression / involutional melancholia / DSM-5 / ICD-11 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520010381187289088 (CiNii: 1520010381187289088)

Proceeding of International Conference:

1.	Hidehiro Umehara, Kazuyuki Matsumoto, Tomohiko Nakayama, Hiroya Matsuda, Masahito Nakataki, Takaki Fukumori, Munenaga Koda, Kikuchi Keita, XIN KANG, Minoru Yoshida and Shusuke Numata : Deep Learning-Derived Multimodal Emotional Discordance During Anger Narratives and Its Association With Depression and Suicidal Ideation in Adolescents and Young Adults: The Moderating Role of Autistic Traits, 27th World Congress of IACAPAP 2026, Jul. 2026.
2.	Toshiki Takanabe, Kazuyuki Matsumoto, Keita Kiuchi, Kashihara Kotaro, Minoru Yoshida, XIN KANG, Tomohiko Nakayama, Takaki Fukumori, Munenaga Koda, Hidehiro Umehara, Masahito Nakataki and Shusuke Numata : Construction of a Stress Estimation Model Using Multimodal Features, Lecture Notes in Networks and Systems, Advances in Natural Language Processing and Information Retrieval , 2025 9th International Conference on Natural Language Processing and Information Retrieval (NLPIR2025), 1904, 888-899, Fukuoka, Dec. 2025. (Summary) This study investigated methods for estimating stress states from video data. An online counseling dataset (50 individuals) was used as the evaluation and training dataset, while a depression counseling dataset (84 individuals) served as the training dataset. Features from speech, audio, and image data were extracted using multiple feature extraction models. To identify effective combinations of the 10 feature types, we performed 50-fold cross-validation using multiple machine learning algorithms. Results showed a stress level estimation accuracy of 0.8 when combining multiple audio, image, and language features and adding the depression interview dataset to the training data. Future work aims to develop a practical model for stress screening.
3.	Tomohiko Nakayama, Hiroaki Edo, Yoshida Tomohiro, Matsumoto Yui, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : Nortriptyline Therapy of Treatment-Resistant Depression: two case reports, The CINP 2021 Virtual World Congress, Online, Feb. 2021.

Proceeding of Domestic Conference:

1.	Kaname Nakayama, Kazuyuki Matsumoto, Minoru Yoshida, XIN KANG, Takaki Fukumori, Munenaga Koda, Keita Kiuchi, Hidehiro Umehara, Tomohiko Nakayama, Masahito Nakataki and Shusuke Numata : A Multimodal Emotion Recognition System Applicable to Both Individuals with Depressive Tendencies and Healthy Controls, 第40回人工知能学会全国大会講演論文集, 1Yin-B-08, Jun. 2026. (Summary) This study proposes a multimodal emotion estimation system applicable to both depressed and healthy individuals.Conventional models often fail on depressed subjects as their blunted affect is treated as noise . We address this by focusing on the "emotional inconsistency" between verbal context (topic) and physical expressions. Our method integrates audio, text, and video features with topic and depression indicators, using a mixed training dataset. This approach establishes a healthy "standard" to detect depressive "distortions" as significant features .Experiments demonstrate robust estimation across mental states, identifying context and vocal prosody as critical indicators. (Keyword) depressive state / multimodal emotion recognition / neural network / Mixed-Data Learning
2.	塩田恭史, Tomohiko Nakayama, Masahito Nakataki and Shusuke Numata : うつ病性昏迷・カタトニアを呈した高齢者に電気けいれん療法が有効であった一例, 第37回日本老年医学会四国地方会, Feb. 2026.
3.	山口雄大, Mariko Aoki, Yuri Yoshida, Tomohiko Nakayama, Masahito Nakataki and Shusuke Numata : 精神症状により身体的治療に意思決定支援を要した2症例, 【第65回中国・四国精神神経学会(2025.11.27-28 山口)】, Nov. 2025.
4.	上山佑一郎, Hiroya Matsuda, Tomohiko Nakayama, Masahito Nakataki and Shusuke Numata : 修正型電気けいれん療法中に遷延する高振幅徐波を認めた2症例の検討, 【第65回中国・四国精神神経学会(2025.11.27-28 山口)】, Nov. 2025.
5.	Tomohiko Nakayama, Masahito Nakataki and Shusuke Numata : 徳島大学病院における認知行動療法の教育体制構築に関する検討, 第25回日本認知療法・認知行動療法学会, Nov. 2025.
6.	Tomohiko Nakayama, Yui Matsumoto, Yukiko Tomioka, Naoki Yamada, Masahito Nakataki and Shusuke Numata : 長期間維持電気けいれん療法を施行している遅発緊張病の一例, 第36回日本総合病院精神医学会総会, Nov. 2023.
7.	塩田恭史, Tomohiko Nakayama, Naoki Yamada, Masahito Nakataki and Shusuke Numata : 脳梗塞と転換症状の鑑別を要したうつ病の一例, 第63回中国・四国精神神経学会, Nov. 2023.
8.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, Yui Matsumoto, Tomohiro Yoshida, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 大うつ病性障害患者における治療前後の血中代謝物濃度の変化, 第45回日本生物学的精神医学会年会, Nov. 2023.
9.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, Yui Matsumoto, Tomohiro Yoshida, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 双極性障害における血中代謝物の変化, 第33回日本臨床精神神経薬理学会学術集会, Sep. 2023.
10.	Tomohiko Nakayama, Ryutaro Muguruma, Saaya Tada, Mika Takahara, Ryosuke Miyamoto, Masahito Nakataki, Yuishin Izumi and Shusuke Numata : 難治性うつ病として治療中にレビー小体病が明らかとなった1症例, 第22回日本早期認知症学会学術大会, Sep. 2022.
11.	Yukiko Tomioka, Makoto Kinoshita, Tomohiko Nakayama, Hidehiro Umehara, Masahito Nakataki and Shusuke Numata : 統合失調症患者におけるDNMT1と3aの遺伝子発現量の検討, 第16回日本統合失調症学会, Mar. 2022.
12.	Ryutaro Muguruma, 多田紗彩, Tomohiko Nakayama, Makoto Kinoshita, Masahito Nakataki and Shusuke Numata : うつ病の治療経過中にパーキンソン病の併存が明らかになった1症例, 【第61回中国・四国精神神経学会, Nov. 2021.
13.	Mariko Aoki, Tomohiko Nakayama, Yukiko Tomioka, Makoto Kinoshita, Masahito Nakataki and Shusuke Numata : 診断に苦慮した遅発緊張病の一例, 第61回中国・四国精神神経学会, Nov. 2021.

Et cetera, Workshop:

1.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 双極性障害における血中メタボローム解析, 第42回躁うつ病の薬理・生化学的研究懇話会, Oct. 2023.
2.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 双極性障害における血中代謝物の変化, 第13回脳科学クラスターミニリトリート, Feb. 2022.
3.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Shusuke Numata, Akira Takahashi, 岡本泰昌 and Tetsuro Ohmori : うつ病におけるキヌレニン経路の変化, 第40回躁うつ病の薬理・生化学的研究懇話会, Oct. 2021.
4.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Shusuke Numata, Akira Takahashi, 岡本泰昌 and Tetsuro Ohmori : うつ病におけるキヌレニン経路の変化, 第12回脳科学クラスターミニリトリート, Feb. 2021.
5.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Shusuke Numata, Akira Takahashi, 岡本泰昌 and Tetsuro Ohmori : うつ病におけるキヌレニン経路の変化, 第5回メタボロームシンポジウム, Dec. 2020.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Search by Researcher Number (30872147)